As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Articles
-
-
The effectiveness of cognitive- behavioral therapy on quality of life in women with hypothyroidism in the reproductive age: a randomized controlled trial
-
Adequate timing and constant supervision are the keys for successful implementation of levothyroxine or levothyroxine/paracetamol absorption test
-
Time-dependent changes in FT4 and FT3 levels measured using mass spectrometry after an acute ingestion of excess levothyroxine in a case with hypothyroidism
-
Should radioiodine now be first line treatment for Graves’ disease?
-
The thyroid gland and the process of aging; what is new?
-
Assessment of Japanese iodine intake based on seaweed consumption in Japan: A literature-based analysis
-
The mechanisms of atrial fibrillation in hyperthyroidism
-
Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state
-
Spectrum of lithium induced thyroid abnormalities: a current perspective
Aims and scope
Thyroid Research is an online journal that aims to present the newest knowledge related to thyroid hormones, thyroid diseases and any related fields. The journal’s regular readership includes researchers, clinicians and healthcare providers across the world.
Thyroid Research encompasses a wide range of thyroidology topics including, diagnosis, pharmacological and other treatment methods, invasive treatment, physiological mechanisms of thyroid hormone action and regulation, immunological aspects, genetics, new guidelines in disease management, thyroid related diseases and complications.
Featured article: Should radioiodine now be first line treatment for Graves’ disease?
In this commentary by Onyebuchi E. Okosieme, Peter N. Taylor and Colin M. Dayan, the authors examine evidence from treatment related mortality studies in hyperthyroidism and discuss their implications for future Graves’ disease treatment strategies.
Prof Bijay Vaidya, Editor-in-Chief
Bijay Vaidya is Consultant Endocrinologist at the Royal Devon & Exeter Hospital, and Honorary Clinical Professor at the University of Exeter Medical School, United Kingdom. He obtained his MBBS degree from the Darbhanga Medical College, Darbhanga, India and a PhD from the University of Newcastle upon Tyne, United Kingdom.
He has clinical and research interest in thyroid diseases, particularly thyroid disorders in pregnancy. He has served as Treasurer and an Executive Committee Member of the British Thyroid Association, and is a member of the Clinical Committeee of the UK Society for Endocrinology and the Thyroid Eye Disease Amsterdam Declaration Implementation Group UK (TEAMeD UK). He has served on the ETA Guidelines Task Forces for ‘Non-autoimmune hyperthyroidism due to TSHR mutations’ and ‘Subclinical hypothyroidism in pregnant women and children’ and the Royal College of Physicians Guidelines Task Force for ‘Management of Thyroid Eye Disease’.
Prof Vaidya has co-authored over 100 papers in peer-reviewed journals.
Advertisement
Annual Journal Metrics
-
Speed
44 days to first decision for reviewed manuscripts only
39 days to first decision for all manuscripts
89 days from submission to acceptance
16 days from acceptance to publication
Citation Impact
1.778 - Source Normalized Impact per Paper (SNIP)
0.355 - SCImago Journal Rank (SJR)
1.370 - CiteScore
Usage
163,036 Downloads
38 Altmetric mentions
Advertisement
